Authors: Maung, HM Elangovan, L Frazao, JM Bower, JD Kelley, BJ Acchiardo, SR Rodriguez, HJ Norris, KC Sigala, JF Rutkowski, M Robertson, JA Goodman, WG Levine, BS Chesney, RW Mazess, RB Kyllo, DM Douglass, LL Bishop, CW Coburn, JW

Citation: Hm. Maung et al., Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1 alpha-hydroxyvitamin D-2) in dialysis patients with secondary hyperparathyroidism: A sequential comparison, AM J KIDNEY, 37(3), 2001, pp. 532-543

Authors: Frazao, JM Elangovan, L Maung, HM Chesney, RW Acchiardo, SR Bower, JD Kelley, BJ Rodriguez, HJ Norris, KC Robertson, JA Levine, BS Goodman, WG Gentile, D Mazess, RB Kyllo, DM Douglass, LL Bishop, CW Coburn, JW

Citation: Jm. Frazao et al., Intermittent doxercalciferol (1 alpha-hydroxyvitamin D-2) therapy for secondary hyperparathyroidism, AM J KIDNEY, 36(3), 2000, pp. 550-561

Authors: Goodman, WG Frazao, JM Goodkin, DA Turner, SA Liu, W Coburn, JW

Citation: Wg. Goodman et al., A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism, KIDNEY INT, 58(1), 2000, pp. 436-445

Authors: Coburn, JW Elangovan, L Goodman, WG Frazao, JM

Citation: Jw. Coburn et al., Calcium-sensing receptor and calcimimetic agents, KIDNEY INT, 56, 1999, pp. S52-S58